June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Effect of Autologous Platelet-rich Plasma Eye Drops in the Treatment of Dry Eye Disease (DED)
Author Affiliations & Notes
  • Jennifer Beth Nadelmann
    Ophthalmology, Scheie Eye Institute, Philadelphia, Pennsylvania, United States
  • Vatinee Y Bunya
    Ophthalmology, Scheie Eye Institute, Philadelphia, Pennsylvania, United States
  • Gui-Shuang Ying
    Ophthalmology, Scheie Eye Institute, Philadelphia, Pennsylvania, United States
  • Peiying Hua
    Ophthalmology, Scheie Eye Institute, Philadelphia, Pennsylvania, United States
  • Mina Massaro-Giordano
    Ophthalmology, Scheie Eye Institute, Philadelphia, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Jennifer Nadelmann, None; Vatinee Bunya, Bausch & Lomb--grant support (F), EP 3210201 (P), National Eye Institute: R01 EY026972 (F), Research to Prevent Blindness (F), US 10,360,819 (P), US 10,783,505 (P); Gui-Shuang Ying, None; Peiying Hua, None; Mina Massaro-Giordano, Lynthera (I), PRN (I)
  • Footnotes
    Support  Vision Core Grant P30 EY001583, Research to Prevent Blindness and National Eye Institute: R01 EY026972
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 1234. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jennifer Beth Nadelmann, Vatinee Y Bunya, Gui-Shuang Ying, Peiying Hua, Mina Massaro-Giordano; Effect of Autologous Platelet-rich Plasma Eye Drops in the Treatment of Dry Eye Disease (DED). Invest. Ophthalmol. Vis. Sci. 2021;62(8):1234.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Platelet rich plasma (PRP) is an autologous preparation that concentrates platelets in a small volume of plasma that has been used to treat ocular surface diseases. The purpose of this study was to determine if treatment with autologous PRP eye drops improved symptoms and signs of dry eye disease (DED).

Methods : A retrospective case series was conducted of patients who were prescribed autologous PRP eye drops for treatment of ocular surface disease. Subjects were excluded if they did not have a follow-up visit, underwent intraocular surgery prior to their follow-up visit, previously received nerve growth factor treatments or did not have a baseline examination with photography. Symptoms were assessed using the Ocular Surface Disease Index (OSDI) and subject report. Patients also underwent a slit lamp exam, which included ocular surface staining with fluorescein and lissamine green.

Results : The charts of 47 patients with a history of ocular surface disease were included who had been prescribed PRP drops. 64 eyes of 32 patients had evaluable photographs of lissamine green staining taken at the baseline and at follow-up. The mean age at the baseline visit was 60 years (SD 13.3) and there were 39 (83%) females. Thirteen patients (28%) had a history of ocular graft-versus-host disease. Sixteen patients (34%) had a history of Sjögren’s syndrome and four patients (8.5%) had Rheumatoid arthritis. The average time of follow-up was 182.7 days, and 162.6 days for those who had follow-up photographs done. There was a statistically significant decrease in OSDI score from baseline to follow-up (39.5 vs 30.8 points, p=0.02). Among the 64 eyes included, 9 (14.1%) eyes had an improvement in conjunctival lissamine green staining (by ≥ 1 point) at follow-up, 49 (76.6%) eyes had stable staining and 6 (9.4%) eyes had increased staining (by ≥ 1 point) at follow-up. Among the 20 eyes with Schirmer testing, there was a borderline significant increase in score from baseline to follow-up visit (5.9 vs. 9.7, p=0.06).

Conclusions : We found that treatment with PRP drops was associated with a significant improvement in OSDI score for patients with ocular surface disease. The majority of eyes treated had stable or decreased lissamine green conjunctival staining at follow-up. Future larger prospective studies are needed to further evaluate the efficacy of PRP drops for treating ocular surface disease.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×